Journal News

MCP: This protein makes
antibody drugs work

Laurel Oldach
November 01, 2019

Hundreds of therapeutic antibody drugs target cell-surface molecules in cancers and other diseases. But different patients respond differently to antibody therapy, and doctors struggle to predict who will benefit most.

CD 16 receptors
An artist’s rendering shows CD16 receptors on a natural killer cell (blue) binding to the constant region of an antibody (orange) that also is bound to a target molecule.

Except for a few used to ferry drugs or toxins to a specific cell population, most antibodies work by recruiting the immune system. When natural killer cells, the body’s tiny assassins, recognize antibodies coating a target cell, the NK cells latch onto the target and kill it.

Kashyap Patel, a grad student at Iowa State University, studies the receptor CD16a, receptor protein on natural killer cells that recognizes and binds to antibodies. Patel and his advisor, Adam Barb, now a professor at the University of Georgia, were interested in changes to CD16a that might underlie binding changes.

“CD16a in our bodies is different than the CD16a that’s used to test monoclonal antibodies,” Patel said. Whereas the recombinant version used in laboratories has limited posttranslational modifications, the human version is glycosylated at five different sites. Glycosylation, which happens in the endoplasmic reticulum, can add complex branched structures to a protein; those modifications can alter proteins’ binding characteristics and could in principle make CD16a more or less likely to bind to antibodies.

Scientists know that a genetic polymorphism near one N-glycosylation site in CD16a can influence how well antibody treatment works. It isn’t clear whether that polymorphism affects glycans directly or whether genetic changes that do affect glycans affect CD16a-antibody binding. Studying the variations in glycan structure at each site is difficult, because isolating enough CD16a from a single person to analyze poses a technical challenge.

In a recent article in the journal Molecular & Cellular Proteomics, Patel, Barb and colleagues report that they studied post-translational modifications to CD16a in glycopeptide samples harvested from the natural killer cells of individual plasma donors. Then they used glycomics tools to determine the structures of the glycans.

“We weren’t expecting the variability we saw,” Patel said. At five sites in CD16a, the team found substantial variability in the structure of glycans — both among the donors and within each individual.

The researchers don’t know yet what to make of the glycan variability, because the donor pool was small and few studies of this type have been done. However, now that the protocol for studying glycan composition from a single person is worked out, Barb’s lab hopes to determine whether changes to that composition affect the immune system’s response to antibody therapy.

When Patel started this project, he didn’t know much about protein glycosylation, but he said he intends to keep studying it as a postdoctoral fellow.

“Once you see a protein with N-glycans on it, you cannot unsee it. You can’t ignore it.”

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Stopping the devil in the dust
Feature

Stopping the devil in the dust

April 07, 2020

As clinicians, veterinarians and research scientists close in on potential vaccines for the devastating fungal illness Valley fever, the largest barrier likely remains outside the lab.

Life's little oscillations
News

Life's little oscillations

April 05, 2020

Concentrations of molecules rise and fall, genes switch on and off, and circadian clocks keep time. These biochemical fluctuations are crucial for myriad biological needs, and cells couldn't function without them.

A small trial finds that hydroxychloroquine is not effective for treating coronavirus
News

A small trial finds that hydroxychloroquine is not effective for treating coronavirus

April 05, 2020

Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney
Journal News

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney

April 03, 2020

In the inaugural JBC Methods Madness Tournament, cryo­–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% —​ a margin thinner than shaved ice. 

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.